All

The safety and effectiveness of biological products depend on the precise implementation of downstream purification processes.

In the wave of biomanufacturing, pilot platforms are highly anticipated - they are the "bridge" connecting laboratory research and development with industrial production, and a key link in promoting the landing of innovative achievements.

As the core equipment in bioengineering, the manufacturing and operational details of bioreactors directly affect production efficiency and product quality.

In the biopharmaceutical industry, there exists an invisible yet crucial "red line" - bacterial endotoxin.

Recently, a colleague roasted: During an on-site inspection, the expert pointed out that the weld seam of a certain pipeline was located right below the support and hanger, and requested rectification. Many people were wondering, "How could the weld seam be in the wrong position? Isn't this too nitpicking?"

"40% of the fermentation broth was spilled" when the tank was being placed? Don't laugh, this can really happen

Beneath the halo of this GLP-1 "star drug", a larger strategy is quietly advancing - Eli Lilly is positioning gene therapy as the next core of growth.

Hyaluronic acid (HA), as a natural polysaccharide, is widely distributed in human skin, joint fluid, and connective tissue, and is a key component for maintaining skin moisture and elasticity.

When the cell culture system in a 200L pilot tank is scaled up "proportionally" to a 2000L pilot tank, phenomena such as yield fluctuations, metabolic disorders, and cell apoptosis are often not simply due to operational errors.

In the field of bioengineering, I often hear people say, "Our bacterial strains are particularly good, with high expression levels, but the results are not good after scaling up."

Based on efficient and stable biocatalysts, precise control of environmental parameters, directional guidance of metabolic flow, combined with real-time monitoring and feedback, while ensuring sterility, ultimately achieving efficient and stable synthesis of the target product.

AI and automation are driving the upgrade of this core capability

A few days ago, I had a meeting with a client who wrote the old saying again in the URS:

The internal cleaning of the fermentation tank must be 100% covered and there must be no dead corners

The safety and effectiveness of biological products depend on the precise implementation of downstream purification processes.